We serve Chemical Name:3-Bromo[1,2,4]triazolo[4,3-a]pyridine CAS:4922-68-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:3-Bromo[1,2,4]triazolo[4,3-a]pyridine
CAS.NO:4922-68-3
Synonyms:3-Bromo[1,2,4]triazolo[4,3-a]pyridine;3-Bromo-[1,2,4]Triazolo[4,3-a]Pyridine;1,2,4-Triazolo[4,3-a]pyridine, 3-bromo-
Molecular Formula:C6H4BrN3
Molecular Weight:198.020
HS Code:2933990090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:1.9±0.1 g/cm3
Index of Refraction:1.751
PSA:30.19000
Exact Mass:196.958847
LogP:2.11
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 3-Bromo[1,2,4]triazolo[4,3-a]pyridine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1,2,4-Triazolo[4,3-a]pyridine, 3-bromo- physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-Bromo[1,2,4]triazolo[4,3-a]pyridine Use and application,3-Bromo-[1,2,4]Triazolo[4,3-a]Pyridine technical grade,usp/ep/jp grade.
Related News: The mode of cooperation between domestic API companies and large international companies can lower the export threshold. 3-Bromo[1,2,4]triazolo[4,3-a]pyridine manufacturer Fate Therapeutics, Inc. recently announced new in vivo preclinical data for FT819, its first off-the-shelf, iPSC-derived chimeric antigen receptor (CAR) T-cell product candidate, at the 61st American Society of Hematology (ASH) Meeting and Exposition in Orlando, FL. 3-Bromo[1,2,4]triazolo[4,3-a]pyridine supplier The Company��s immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs). 3-Bromo[1,2,4]triazolo[4,3-a]pyridine vendor Fate Therapeutics, Inc. recently announced new in vivo preclinical data for FT819, its first off-the-shelf, iPSC-derived chimeric antigen receptor (CAR) T-cell product candidate, at the 61st American Society of Hematology (ASH) Meeting and Exposition in Orlando, FL. 3-Bromo[1,2,4]triazolo[4,3-a]pyridine factory The new restrictions on foreign nationals begin on February 3, Prime Minister Jacinda Ardern announced in a press release Sunday.